Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Zuardi AW.

Rev Bras Psiquiatr. 2008 Sep;30(3):271-80. Review.

2.

Safety and side effects of cannabidiol, a Cannabis sativa constituent.

Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA.

Curr Drug Saf. 2011 Sep 1;6(4):237-49. Review.

PMID:
22129319
3.

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Zuardi AW, Crippa JA, Hallak JE, Moreira FA, GuimarĂ£es FS.

Braz J Med Biol Res. 2006 Apr;39(4):421-9. Epub 2006 Apr 3. Review.

4.

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW.

Rev Bras Psiquiatr. 2012 Jun;34 Suppl 1:S104-10. Review. English, Portuguese.

5.

Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.

Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G.

Phytother Res. 2009 May;23(5):597-602. doi: 10.1002/ptr.2625. Review.

PMID:
18844286
6.

Cannabidiol: an overview of some pharmacological aspects.

Mechoulam R, Parker LA, Gallily R.

J Clin Pharmacol. 2002 Nov;42(11 Suppl):11S-19S. Review.

PMID:
12412831
7.

Cannabidiol--recent advances.

Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO.

Chem Biodivers. 2007 Aug;4(8):1678-92. Review.

PMID:
17712814
8.

Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects.

Mechoulam R, Hanus L.

Chem Phys Lipids. 2002 Dec 31;121(1-2):35-43. Review.

PMID:
12505688
9.

A systematic review of the antipsychotic properties of cannabidiol in humans.

Iseger TA, Bossong MG.

Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Epub 2015 Feb 7. Review.

PMID:
25667194
10.

Cannabidiol: a promising drug for neurodegenerative disorders?

Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L.

CNS Neurosci Ther. 2009 Winter;15(1):65-75. doi: 10.1111/j.1755-5949.2008.00065.x. Review.

PMID:
19228180
11.

Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.

Morgan CJ, Curran HV.

Br J Psychiatry. 2008 Apr;192(4):306-7. doi: 10.1192/bjp.bp.107.046649.

12.

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.

Russo E, Guy GW.

Med Hypotheses. 2006;66(2):234-46. Epub 2005 Oct 4.

PMID:
16209908
13.
14.

Cannabidiol as a potential treatment for psychosis.

Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP.

Eur Neuropsychopharmacol. 2014 Jan;24(1):51-64. doi: 10.1016/j.euroneuro.2013.11.002. Epub 2013 Nov 15. Review.

PMID:
24309088
15.

Does cannabidiol protect against the negative effects of THC?

Henquet C, Kuepper R.

Br J Psychiatry. 2010 Oct;197(4):259-60. doi: 10.1192/bjp.bp.110.081380.

16.

Toward drugs derived from cannabis.

Mechoulam R, Carlini EA.

Naturwissenschaften. 1978 Apr;65(4):174-9. Review.

PMID:
351429
17.

On the pharmacological properties of Delta9-tetrahydrocannabinol (THC).

Costa B.

Chem Biodivers. 2007 Aug;4(8):1664-77. Review.

PMID:
17712813
18.

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, GuimarĂ£es FS.

Curr Pharm Des. 2012;18(32):5131-40. Review.

PMID:
22716160
19.

Clinical potential of minocycline for schizophrenia.

Miyaoka T.

CNS Neurol Disord Drug Targets. 2008 Oct;7(4):376-81. Review.

PMID:
18991666
20.

Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.

Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, dos Santos AC, Teixeira AL, Hallak JE, Crippa JA.

J Psychopharmacol. 2014 Nov;28(11):1088-98. doi: 10.1177/0269881114550355. Epub 2014 Sep 18.

Supplemental Content

Support Center